Peptides DB
Research-centric peptide and protocol reference hub

CJC-1295 without DAC (Modified GRF 1-29) record · updated 18h ago

Muscle & body compMetabolic & appetiteGrade A · human clinicalResearch use only
All 8 studiesJump to the evidenceCompare
What is CJC-1295 without DAC (Modified GRF 1-29) used for?

CJC-1295 without DAC (Modified GRF 1-29) is a short-acting GHRH analog studied for its ability to stimulate pulsatile growth hormone release from the pituitary.

How it works: GHRH (1–29) analog, modified

Primarily researched for · Muscle & body compRoute · Subcutaneous injection

Development stage

where CJC-1295 without DAC (Modified GRF 1-29) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 22 registered trials. It describes the research record, not a recommendation.

Identity
NameCJC-1295 without DAC (Modified GRF 1-29)
Chain length—
Molecular weight—
Formula—
Structure type—
ClassMuscle
Research levelModerate Research
Discovered byCurated master list · 2026
Pharmacology
MechanismGHRH (1–29) analog, modified
RouteSubcutaneous injection
Half-life~30 min
Time to peak—
Duration—
Extraction confidence0.60
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Oct 10, 2026. How this works →
Research stats
Total studies8
Human / animal / cellular5 / 3 / 0
Highest trial phasePreclinical
Years covered1993–2026
Latest study8d ago
Publication history
19932026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

8 rowsOpen in the library →
StudyTypeYearSummary depth
Glucocorticoids may inhibit growth hormone release by enhancing beta-adrenergic responsiveness in hypothalamic somatostatin neurons.
FindingGH peak: 10.7 +/- 3.9 vs. 20.3 +/- 5.5 micrograms/L; DEX vs. P study, respectively, P < 0.05.
Human1993Full text read0.80
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
FindingMean plasma GH concentrations increased by 2- to 10-fold for 6 d or more.
Human2006Full text read0.80
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
Finding7.5-fold increase in basal GH levels, P < 0.0001.
Human2006Full text read0.80
Synergistic antibacterial and osteogenic properties of micro-arc oxidation GO@Ag/SF composite coatings for the repair of infectious bone defects.
FindingInhibition rates against S. aureus and E. coli were up to 98.3 ± 1.2%.
Animal2026Full text read0.80
Prevalence and determinants of parasitic contamination on fruits and vegetables in gedeo zone, Ethiopia: Implications for foodborne disease.
Finding33.5% contamination rate among 442 samples.
Human2026Full text read0.80
Synthetic β-amino acid polymer promoting keratocyte adhesion and corneal regeneration.
FindingComparable keratocyte adhesion to RGD peptide.
Animal2026Full text read0.70
An orthogonal transcription system enables high-efficiency rescue of measles virus-based vaccine vectors against multiple pathogens.
FindingRescue efficiency enhanced by more than 50-fold.
Animal2026Full text read0.80
A Step-Up Underwater Endoscopic Mucosal Resection Strategy with Rescue Underwater Injection Endoscopic Mucosal Resection for Non-Pedunculated Colorectal Lesions.
FindingEn bloc resection achieved in 100% of lesions.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching CJC-1295 without DAC (Modified GRF 1-29) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much CJC-1295 without DAC (Modified GRF 1-29) is discussed should be drawn from it.